Newcells Biotech is a technology company.
Newcells Biotech has raised $21.2M across 6 funding rounds.
Newcells Biotech has raised $21.2M in total across 6 funding rounds.
Newcells Biotech has raised $21.2M in total across 6 funding rounds.
Newcells Biotech's investors include Northstar Ventures.
Newcells Biotech is a UK-based biotechnology company that develops advanced in vitro tissue models derived from induced pluripotent stem cells (iPSCs) to accelerate drug discovery and improve clinical translation for pharmaceutical and biotech firms[1][2][3][4]. These predictive models replicate human organs like the kidney, retina, and lung, enabling accurate assessment of drug efficacy, safety, toxicology, and ADME (absorption, distribution, metabolism, excretion) while reducing animal testing and development costs[2][3][4]. With 42 employees and headquarters in Newcastle upon Tyne, the company serves global pharma, biotech, and academic clients through products like kidney nephron, retinal organoid, and lung airway models, demonstrating strong growth via venture funding and worldwide collaborations[1][4][6].
Founded in 2015 as a spin-out from Newcastle University, Newcells Biotech emerged from pioneering UK research in iPSC technology, led by a team central to one of Europe's leading reprogramming centers[1][4][6]. The founders leveraged university expertise in producing iPSCs and differentiating them into diverse cell and tissue types to address inefficiencies in drug discovery[1][4]. Early traction came with a £0.15m investment from Northstar Ventures in 2015, enabling expansion in cell production and model development, followed by a £2m round in 2018 led by Northstar and NVM Private Equity to commercialize services and enter the US market[6]. A pivotal moment was during the COVID-19 pandemic, when collaboration with Liverpool School of Tropical Medicine produced a human upper airway model for virus studies and drug testing[6].
Newcells Biotech stands out in the biotech tools space through these key strengths:
Newcells Biotech rides the organoid and iPSC revolution in biotech, addressing the 90%+ preclinical-to-clinical failure rate by providing human-relevant models that enhance translation and de-risk drug development[3][4]. Timing aligns with rising regulatory pressure to minimize animal testing, surging demand for precision medicine, and post-COVID emphasis on respiratory/lung models[2][6]. Market forces like pharma's push for cost-effective ADME/toxicity screening and gene therapy growth favor its kidney, retina, and lung focus[1][2]. By partnering with global organizations, it influences the ecosystem toward more ethical, efficient R&D, supporting safer therapies and fostering UK life sciences innovation[2][4][6].
Newcells Biotech is poised for expansion with recent funding from founders, VCs, and private equity, scaling its pipeline and facilities amid biotech tools demand[4][6]. Upcoming trends like AI-integrated screening, expanded iPSC libraries (e.g., 1,500 lines from its center), and gene therapy applications will shape its trajectory, potentially capturing more US/EU market share[1][2]. Its influence may evolve into a full CRO partner, driving higher clinical success rates and tying back to its core mission: reliable *in vitro* data that accelerates patient therapies[3][4].
Newcells Biotech has raised $21.2M across 6 funding rounds. Most recently, it raised $2.0M Venture Round in December 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2024 | $2.0M Venture Round | Northstar Ventures | |
| Feb 1, 2024 | $3.0M Venture Round | Northstar Ventures | |
| Mar 1, 2023 | $6.0M Series A | Northstar Ventures | |
| Feb 1, 2021 | $7.0M Seed | Northstar Ventures | |
| Jul 1, 2018 | $3.0M Seed | Northstar Ventures | |
| Aug 1, 2015 | $240K Seed | Northstar Ventures |